Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights Polpharma’s digital approach and the company’s long-term vision for sustained success across the region.
Our international markets are growing rapidly; therefore, this segment is increasingly important, and we have plans to widen our regional reach in the upcoming future by defining more core markets
